Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor/Wellcome

Executive Summary

Sign letter of intent to form alliance for the development and marketing of certain of Centocor's monoclonal antibody-based agents for the treatment of cancer, including Penorox (17-lA), which has completed a Phase III trial in Germany for colorectal cancer. Under the deal, announced Sept. 17, Wellcome plc will contribute to the clinical development of Panorex and the other compounds and market and sell any approved drugs in most parts of the world. Wellcome will acquire an equity stake in Centocor of 2 mil. newly issued shares, which will represent just under 5% of the total share capital of Centocor, and make other future payments.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel